科研成果：

省部共建课题“黄芪甲苷对糖尿病肾病早期足细胞α3β1 整合素及整合素连接酶表达的影响”（ WKJ2009-2-017）负责人。浙江省自然基金“LY12H05001黄芪甲苷抑制早期糖尿病肾病足细胞凋亡的新机制”，“ LY14H050004    黄芪甲苷通过p130Cas抑制糖尿病肾病足细胞足突融合的研究” 参与者。
发表文章如下：
1.Chen J, Gui D, Chen Y,et al. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition[J]. Biochem Pharmacol. 2008 Sep 15;76(6):796-804.
2.陈建国, 桂定坤, 牟利军, 等. 黄芪甲苷对高糖刺激下的足细胞黏附功能的保护作用及机制[J]. 中华肾脏病杂志, 2009, 25(3): 227-232.
3.Gui D, Guo Y,  Chen J, et al. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo[J]. PLoS One. 2012;7(6):e39824.
4.Gui D, Huang J, Chen J, et al.Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression[J]. Cytokine. 2013 Mar;61(3):970-7.
5.  罗蕴龄, 陈宜方, 陈建国，等. 黄芪甲苷对糖尿病肾病大鼠足细胞的影响及其机制研究[J]. 浙江医学, 2014 (7).
6.Chen J, Chen Y, Luo Y, et al. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats[J]. European journal of pharmacology, 2014, 736: 86-94.
7. Chen Y, Gui D, Chen J, et al. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats[J]. Cell Physiol Biochem. 2014;33(6):1975-87.